Avesthagen, the integrated systems biology platform company is looking at the possibility of collaborative research with biotechnology companies in Thailand. Early this year, the company collaborated with Malaysian Biotechnology Corporation to manufacture bio-similars.

The company is developing clinically validated botanical bio-actives, derived from Indian medicinal plants, as well as the development of a range of bio-similar drugs. The Thailand government had identified Avesthagen along with Infosys among the information technology and biotechnology companies in Bangalore to be visited by its Deputy Prime Minister Kosit Panpirmras along with a 35-member trade delegation.

The high level 35-member delegation included senior representatives from the government and private companies, from various sectors such as the Board of Investment of Thailand, National Science and Technology Agency, banks and software.

According to Dr Villoo Morawalla Patell, vice chairperson and founder, the Thailand delegation visit establishes the impact that the company has made on the global biotechnology industry.

Avesthagen focuses on achieving convergence of food, pharma and population genetics leading to preventive personalized healthcare. The Bangalore-based company employs 290 people worldwide and has four strategic business units: bioPharmaceuticals, bioNutrition, bioAgriculture and Science and Innovation. Avesthagen’s partners include multiple top 10 global companies in each of its fields of research.

About Avesthagen
Avesthagen is India’s leading fully integrated biotechnology and bioinformatics company, focusing on the convergence between food, pharmaceuticals and clinical genomics leading to preventive personalized medicine. Avesthagen provides innovative solutions for global challenges in agriculture and health problems in the areas of degenerative conditions, metabolic disorders and infectious diseases. Avesthagen, founded in 1998, is a science and discovery based life sciences company that focuses on achieving convergence between food, pharma and population genetics leading to preventive personalized medicine. The company also uses its technology platform and capabilities to provide innovative R&D Services to the global pharma, biotech, food and seed industries (“RPO — Research Process Outsourcing” program). 

---

The company is developing clinically validated botanical bio-actives, derived from Indian medicinal plants, as well as the development of a range of bio-similar drugs.